Physician profile
Charles E Porterfield
NPI 1164486486
$7,705.74
in general payments reported to CMS, 2019-2025
43 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,011 · 2020: $580 · 2021: $926 · 2022: $781 · 2023: $963 · 2024: $1,115 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,335 · Education: $72.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,334.69 |
| Education | $72.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,819.26 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $992.44 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $958.06 | 2019-2025 | Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $607.67 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $348.13 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $312.91 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $278.63 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $251.80 | 2020-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $222.34 | 2023-2024 | Acthar |
| Harmony Biosciences LLC | $196.93 | 2025 | |
| Genentech USA, INC. | $196.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $157.95 | 2019-2023 | |
| Pulmonx Corporation | $144.94 | 2020-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| United Therapeutics Corporation | $108.92 | 2021-2025 | |
| Amgen INC. | $98.14 | 2021-2025 | Tezspire |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $74.49 | 2019-2020 | |
| Axsome Therapeutics, INC. | $70.03 | 2022-2024 | Sunosi |
| Verona Pharma, INC. | $63.08 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $61.41 | 2020-2021 | |
| Shire North American Group INC | $55.66 | 2019 | |
| Philips North America LLC | $53.32 | 2019-2020 | |
| Inspire Medical Systems, INC. | $52.54 | 2023 | Inspire |
| Insmed, INC. | $48.15 | 2023-2025 | Brinsupri, Arikayce |
| Vanda Pharmaceuticals INC. | $46.37 | 2020 | |
| Vifor Pharma, INC. | $41.89 | 2024 | Zemaira, Veltassa |
| Jazz Pharmaceuticals INC. | $38.28 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.64 | 2022-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $36.84 | 2025 | Lumryz |
| Inogen, INC. | $36.38 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Electromed, INC. | $35.23 | 2023-2024 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $33.28 | 2021-2022 | |
| Baxter Healthcare | $33.17 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Teva Pharmaceuticals USA, INC. | $29.01 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $28.75 | 2019 | |
| La Jolla Pharmaceutical Company | $21.43 | 2024 | Giapreza |
| Viatris Specialty LLC | $20.00 | 2025 | Yupelri |
| Tactile Systems Technology INC | $18.27 | 2023 | Flexitouch Plus, Entre Plus |
| Csl Behring | $14.64 | 2021 | |
| Abbvie INC. | $13.80 | 2024 | |
| Merck Sharp & Dohme LLC | $13.71 | 2024 | Winrevair |
| Pfizer INC. | $12.60 | 2019 | |
| Lilly USA, LLC | $12.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $9.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Porterfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.